Sylvie Guichard

Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.

X. Jacq, J. Nissink, I. Hickson, 2013, Journal of medicinal chemistry.

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

E. Wilker, A. Drake, P. Schroeder, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

A. Wei, S. de Botton, Sangmin Lee, 2022, The Lancet. Haematology.

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.

P. Malik, A. Drake, A. Shrestha, 2021, Blood advances.